Bleeding should stop once 2.38 warrants expire

[lakers]

From SO

“As stated, the bad news about the warrants not being exercised is that the company does need the money. The good news is that this will free up 14 million shares which are now unencumbered. That gives the company some leeway to perhaps address debt and interest payments to Deerfield with shares rather than using much needed cash. It might be possible for the company to address the Deerfield issue with 7 million shares or so. This would preserve over $13 million in cash, and extend the cash runway into Q4. If the company can get another $12.5 million milestone related to Dryvaso or even a $15 million milestone related to another UTHR compound, it could be enough breathing room to get to the last week in December to get to the $40 million which could be raised on the $1.60 warrants. That could get the company into Q2 of next year. It is still cutting things quite close, but a path does exist.”
seekingalpha.com/amp/article/4253095-mannkind-afrezza-scripts-jump-close-quarter

[lakers]

Interesting SO’s discussion. Your thoughts?

“Over the last month, many diabetes advocates were excited to see Congress get involved in the pricing of insulin via various hearings. That is great news for diabetics, but less than thrilling news for investors. The big players in insulin have responded with various cost-cutting measures. This dynamic makes life more difficult for Afrezza. With the price gap between Afrezza and other treatments getting bigger, it becomes more challenging for consumers to make the leap to a premium product. Many long-term MannKind investors reveled in seeing big pharma get slapped about on Capitol Hill, but that is in many ways a hollow victory in terms of your investment. It is clear that Afrezza cannot match the cost-cutting ability of the bigger and more established players. If Afrezza is forced into fighting a pricing battle, it will be tough sledding.

The flip side of that discussion might be whether or not Afrezza in the hands of others can open a window to a revenue driver for that entity. There could be a sound argument for Afrezza commanding premium prices that insulates a big player from getting slapped around. It is a tough argument to make, as the consumer market has spoken pretty loudly with low sales, but it is possible that some move could happen.“

[bigchungus91354]

There goes that theory, someone get this stock a bandage!

[peppy]

Apr 15, 2019 9:37:05 GMT -5 bigchungus91354 said:

There goes that theory, someone get this stock a bandage!

Do I have this correct, $1.66 should support?

[bigchungus91354]

Apr 15, 2019 9:45:41 GMT -5 peppy said:

Apr 15, 2019 9:37:05 GMT -5 bigchungus91354 said:

There goes that theory, someone get this stock a bandage!

Do I have this correct, $1.66 should support?

Looks good so far, nice charting!!

[longliner]

The divergent; TD Bid $1.43 ask $2.05 the true "Battleground Stock".